Pharmafile Logo

Wilmington Healthcare appoints new Head of Digital

January 26, 2021 |  

Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.

In his new role, Mikko will develop and drive the strategy and execution of our clients’ intelligence-led and data-driven omni-channel programmes. These combine multiple channels, including OnMedica – an online community providing bitesize, evidence-based Continuing Professional Development (CPD) and other content for GPs and specialist doctors.

Mikko joins Wilmington Healthcare from the Brain Tumour Charity where, as Head of Digital, he led a team responsible for delivering digital marketing and communications plans across the organisation for income generation and to support service delivery.

Prior to that, he was UK Digital Marketing Manager for Pfizer, where he developed the digital strategy for its UK Rare Diseases Business Unit, which became one of the company’s most successful digital engagement ventures, with initiatives such as patient mobile apps, interactive digital detail aids for sales representatives, and a series of multichannel marketing campaigns.

He also led a team of cross functional stakeholders and external agencies to deliver a consumer-facing multichannel awareness campaign for a rare disease, winning a Pfizer global innovation award in the process.

Mikko has also held roles in digital marketing, customer acquisition, and supporter retention at organisations across a range of industries, including publishing, politics, and B2B service delivery.

Simon Grime, of Wilmington Healthcare, says: “We’re delighted to have Mikko on the team and, having worked in both the pharma and healthcare charity sectors, he brings a really valuable blend of digital marketing experience to his new post.

“He will be a fantastic addition to the company, where he will play a key role in shaping our intelligence-led omni-channel marketing strategy and helping our clients deliver the optimal mix of channels to complement their customer engagement strategies.”

- PMLiVE

Ends

This content was provided by Wilmington Healthcare

Company Details

 Latest Content from  Wilmington Healthcare 

How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma

New report shows Traumatic Brain Injury (TBI) is a major threat to older people

A report by healthcare intelligence provider Wilmington Healthcare and the charity, United Kingdom Acquired Brain Injury Forum (UKABIF), shows that many hospital admissions in England for Traumatic Brain Injury (TBI)...

How will Sustainability and Transformation Plans (STPs) change the NHS in 2017?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the impact that STPs will have on the NHS and what this means for pharma.

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

How can the NHS deliver integrated care?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain the changes needed to help the NHS provide a more holistic, joined up experience for patients

How can pharma engage with NHS Vanguards?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore the opportunities for pharma to help NHS vanguards develop new models of care.

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.